H.C. Wainwright lowered the firm’s price target on Ovid Therapeutics (OVID) to $1.50 from $2 and keeps a Buy rating on the shares. Ovid currently trades at a negative enterprise value and remains slated to deliver multiple potential value inflection points over the next 12 months, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
- Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
- Ovid Therapeutics reports Q1 EPS (14c), consensus (13c)
- Ovid Therapeutics sees cash runway into 2H26
- Ovid Therapeutics Advances Pipeline Amid Financial Progress